Lawsuit for Investors in shares of Actinium Pharmaceuticals, Inc. (NYSE: ATNM) announced by the Shareholders Foundation

Core Viewpoint - A lawsuit is pending against Actinium Pharmaceuticals, Inc. for alleged violations of securities laws related to the company's failure to disclose critical information regarding the FDA approval process for its Iomab-B BLA [2] Group 1: Lawsuit Details - The lawsuit was filed by an investor on March 27, 2025, claiming that Actinium Pharmaceuticals did not disclose that data from the Sierra Trial was unlikely to meet FDA guidelines for Iomab-B BLA approval [2] - The plaintiff argues that the additional analyses provided to the FDA, which suggested improved Overall Survival, were also unlikely to satisfy the FDA's requirements [2] - As a result of these alleged omissions, the lawsuit claims that the company's positive statements regarding its business and prospects were materially misleading [2] Group 2: Investor Information - Shareholders who purchased shares of Actinium Pharmaceuticals prior to October 2022 and continue to hold those shares are encouraged to contact the Shareholders Foundation for options related to the lawsuit [1][3] - The Shareholders Foundation provides services related to shareholder issues, including information on securities class actions and legal news relevant to the financial market [3]